title: Stem cell-based approach for the treatment of Parkinson's disease.
abstract: Parkinson's disease (PD) is the second most common neurodegenerative brain disorder which is around 1.5 times more common in men than in women. Currently, drug medications, surgery, and lifestyle changes are common approaches to PD, while all of them focused on reducing the symptoms. Therefore, regenerative medicine based on stem cell (SC) therapies has raised a promising hope. Various types of SCs have been used in basic and experimental studies relevant to PD, including embryonic pluripotential stem cells, mesenchymal (MSCs) and induced pluripotent SCs (iPSCs). MSCs have several advantages over other counterparts. They are easily accessible which can be obtained from various tissues such as bone marrow, adipose tissue, peripheral blood, etc. with avoiding ethical problems. Therefore, MSCs is attractive clinically because there are no related ethical and immunological concerns . Further studies are needed to answer some crucial questions about the different issues in SC therapy. Accordingly, SC-based therapy for PD also needed more complementary evaluation in both basic and clinical study areas.
authors.affiliation: MSc, Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran. goudarzi.p@iums.ac.ir.
authors.forename: Parisa
authors.initials: P
authors.lastname: Goodarzi
authors.affiliation: MD, PhD, Chronic Diseases Research Center, Endocrinology and Metabolism Research Institute & Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran. hr_aghayan@farabi.tums.ac.ir.
authors.forename: Hamid Reza
authors.initials: HR
authors.lastname: Aghayan
authors.affiliation: MD, Endocrinology and Metabolism Research Center , Endocrinology and Metabolism Research Institute, Tehran University of Medical sciences, Tehran, Iran. Larijanib@tums.ac.ir.
authors.forename: Bagher
authors.initials: B
authors.lastname: Larijani
authors.affiliation: PhD, Hematology Department, Faculty of Medicine, Tarbiat Modares University, Tehran, Iran. soleim_m@modares.ac.ir.
authors.forename: Masoud
authors.initials: M
authors.lastname: Soleimani
authors.affiliation: PhD, Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. dehpour@yahoo.com.
authors.forename: Ahmad-Reza
authors.initials: AR
authors.lastname: Dehpour
authors.affiliation: BSc, Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran. mehrsahebjam44@gmail.com.
authors.forename: Mehrnaz
authors.initials: M
authors.lastname: Sahebjam
authors.affiliation: BSc, Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Tehran, Iran. firozehghaderi@yahoo.com.
authors.forename: Firoozeh
authors.initials: F
authors.lastname: Ghaderi
authors.affiliation: MD, PhD, GMP-Compliant Stem Cell Facility, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Research Institute & Brain and Spinal Cord Injury Research Center, Tehran University of Medical Sciences, Shariati Hospital, North Kargar, Tehran, Iran. b_arjmand@farabi.tums.ac.ir.
authors.forename: Babak
authors.initials: B
authors.lastname: Arjmand
keywords: Cellular therapy; Neurodegenerative diseases; Parkinson’s disease; Stem cell